8-KOther EventsExhibits & Filings

Elevance Health, Inc. 8-K Report, Corporate Update (May 30, 2024)

Filed May 30, 2024For Securities:ELV

Summary

Elevance Health, Inc. (ELV) announced on May 29, 2024, the closing of a significant notes offering, raising approximately $2.57 billion in net proceeds. This offering included $600 million in 5.150% Notes due 2029, $1 billion in 5.375% Notes due 2034, and $1 billion in 5.650% Notes due 2054. The company intends to use these funds for general corporate purposes, including working capital, potential acquisitions, debt repayment, and share repurchases. This financing action provides Elevance Health with substantial liquidity to support its strategic initiatives and financial flexibility. Investors should note the specific interest rates and maturity dates associated with each tranche of notes, as well as the terms for redemption and potential change of control provisions that could trigger an accelerated repurchase of the notes. The company's ability to continue incurring debt under the indenture provides further operational flexibility.

Key Highlights

  • 1Closed a notes offering totaling $2.57 billion in net proceeds.
  • 2Issued three tranches of senior unsecured notes: $600M (5.150% due 2029), $1B (5.375% due 2034), and $1B (5.650% due 2054).
  • 3Net proceeds will be used for general corporate purposes, including working capital, acquisitions, debt repayment, and share repurchases.
  • 4The indenture does not restrict the incurrence of additional indebtedness by the company or its subsidiaries.
  • 5Notes are subject to optional redemption by the company prior to maturity, with specific call protection periods.
  • 6A change of control event coupled with a credit rating downgrade could trigger a mandatory offer to purchase the notes at 101% of principal.

Frequently Asked Questions

Elevance Health conducted this notes offering to raise approximately $2.57 billion in net proceeds, which will be used for general corporate purposes. This includes funding working capital needs, potential acquisitions, repaying existing debt (both short-term and long-term), and repurchasing the company's common stock under its share repurchase program.

The company issued three series of notes: $600 million of 5.150% Notes due 2029, $1 billion of 5.375% Notes due 2034, and $1 billion of 5.650% Notes due 2054. Interest is payable semi-annually on June 15 and December 15, commencing December 15, 2024. The notes have varying redemption terms and include provisions related to change of control events.

According to the filing, the Indenture governing these notes does not prohibit or limit the incurrence of additional indebtedness and other liabilities by Elevance Health or its subsidiaries. This indicates the company retains significant financial flexibility to pursue future financing or operational activities.

If a change of control occurs and, in addition, a series of these notes is downgraded below an investment grade rating by Moody's, S&P, and Fitch within a specified period, Elevance Health will be required to make an offer to purchase all of the notes of that affected series at 101% of their principal amount, plus accrued interest.